Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE‐related cardiovascular disease

References

• Manzi S., Meilahn E. N., Rairie J. E., Conte C. G., Medsger T. A., Jr., Jansen‐McWilliams L., et al. Age‐specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408–15
   PubMed Web of Science ®Google Scholar
• Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005; 25: 1776–85
   PubMed Web of Science ®Google Scholar
• Svenungsson E., Jensen‐Urstad K., Heimburger M., Silveira A., Hamsten A., de Faire U., et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887–93
   PubMed Web of Science ®Google Scholar
• Cederholm A., Svenungsson E., Stengel D., Fei G. Z., Pockley A. G., Ninio E., et al. Platelet‐activating factor‐acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 2869–76
   PubMed Web of Science ®Google Scholar
• Sallai K. K., Nagy E., Bodo I., Mohl A., Gergely P. Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors. Scand J Rheumatol 2007; 36: 198–205
   PubMed Web of Science ®Google Scholar
• Manzi S., Selzer F., Sutton‐Tyrrell K., Fitzgerald S. G., Rairie J. E., Tracy R. P., et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51–60
   PubMed Web of Science ®Google Scholar
• Roman M. J., Shanker B. A., Davis A., Lockshin M. D., Sammaritano L., Simantov R., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399–406
   PubMed Web of Science ®Google Scholar
• Freigang S., Horkko S., Miller E., Witztum J. L., Palinski W. Immunization of LDL receptor‐deficient mice with homologous malondialdehyde‐modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998; 18: 1972–82
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115–26
   PubMed Web of Science ®Google Scholar
• Hansson G. K., Libby P., Schonbeck U., Yan Z. Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281–91
   PubMed Web of Science ®Google Scholar
• Binder C. J., Chang M. K., Shaw P. X., Miller Y. I., Hartvigsen K., Dewan A., et al. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8: 1218–26
   PubMed Web of Science ®Google Scholar
• Hansson G. K., Holm J., Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989; 135: 169–75
   PubMed Web of Science ®Google Scholar
• Frostegard J., Ulfgren A. K., Nyberg P., Hedin U., Swedenborg J., Andersson U., et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro‐inflammatory (Th1) and macrophage‐stimulating cytokines. Atherosclerosis 1999; 145: 33–43
   PubMed Web of Science ®Google Scholar
• Svenungsson E., Fei G. Z., Jensen‐Urstad K., de Faire U., Hamsten A., Frostegard J. TNF‐alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 2003; 12: 454–61
   PubMed Web of Science ®Google Scholar
• Svenungsson E., Gunnarsson I., Fei G. Z., Lundberg I. E., Klareskog L., Frostegard J. Elevated triglycerides and low levels of high‐density lipoprotein as markers of disease activity in association with up‐regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2533–40
   PubMed Web of Science ®Google Scholar
• Magalhaes M. B., da Silva L. M., Voltarelli J. C., Donadi E. A., Louzada‐Junior P. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations. Scand J Rheumatol 2007; 36: 442–7
   PubMed Web of Science ®Google Scholar
• Carmena R., Duriez P., Fruchart J. C. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004; III2–7, 109
   Google Scholar
• Nicholls S. J., Rye K. A., Barter P. J. High‐density lipoproteins as therapeutic targets. Curr Opin Lipidol 2005; 16: 345–9
   PubMed Web of Science ®Google Scholar
• Otvos J. D., Jeyarajah E. J., Bennett D. W., Krauss R. M. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992; 38: 1632–8
   PubMed Web of Science ®Google Scholar
• Hurt‐Camejo E., Paredes S., Masana L., Camejo G., Sartipy P., Rosengren B., et al. Elevated levels of small, low‐density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum 2001; 44: 2761–7
   PubMed Web of Science ®Google Scholar
• Borba E. F., Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997; 6: 533–9
   PubMed Web of Science ®Google Scholar
• Borba E. F., Bonfa E., Vinagre C. G., Ramires J. A., Maranhao R. C. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1033–40
   PubMedGoogle Scholar
• Lemne C., Jogestrand T., de Faire U. Carotid intima–media thickness and plaque in borderline hypertension. Stroke 1995; 26: 34–9
   PubMed Web of Science ®Google Scholar
• Linden T., Bondjers G., Camejo G., Bergstrand R., Wilhelmsen L., Wiklund O. Affinity of LDL to a human arterial proteoglycan among male survivors of myocardial infarction. Eur J Clin Invest 1989; 19: 38–44
   Google Scholar
• Skalen K., Gustafsson M., Rydberg E. K., Hulten L. M., Wiklund O., Innerarity T. L., et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417: 750–4
   PubMed Web of Science ®Google Scholar
• Camejo G., Rosengren B., Olson U., Lopez F., Olofson S. O., Westerlund C., et al. Molecular basis of the association of arterial proteoglycans with low density lipoproteins: its effect on the structure of the lipoprotein particle. Eur Heart 1990; 11: 164–73
   PubMed Web of Science ®Google Scholar
• Lada A. T., Rudel L. L. Associations of low density lipoprotein particle composition with atherogenicity. Curr Opin Lipidol 2004; 15: 19–24
   PubMed Web of Science ®Google Scholar
• Chung C. P., Oeser A., Raggi P., Solus J. F., Avalos I., Linton M. F., et al. Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus. Clin Rheumatol 2008; 27: 1227–33
   Google Scholar
• Hurt‐Camejo E., Andersen S., Standal R., Rosengren B., Sartipy P., Stadberg E., et al. Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low‐density lipoproteins. Arterioscler Thromb Vasc Biol 1997; 17: 300–9
   PubMed Web of Science ®Google Scholar
• Elinder L. S., Dumitrescu A., Larsson P., Hedin U., Frostegard J., Claesson H. E. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol 1997; 17: 2257–63
   PubMed Web of Science ®Google Scholar
• Navab M., Berliner J. A., Subbanagounder G., Hama S., Lusis A. J., Castellani L. W., et al. HDL and the inflammatory response induced by LDL‐derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001; 21: 481–8
   PubMed Web of Science ®Google Scholar
• McMahon M., Grossman J., FitzGerald J., Dahlin‐Lee E., Wallace D. J., Thong B. Y., et al. Proinflammatory high‐density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54: 2541–9
   PubMed Web of Science ®Google Scholar
• Borggreve S. E., De Vries R., Dullaart R. P. Alterations in high‐density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003; 33: 1051–69
   PubMed Web of Science ®Google Scholar